metricas

Medicina Clínica

Sugerencias
Medicina Clínica Tratamiento de la oftalmopatía de Graves
Información de la revista
Vol. 156. Núm. 4.
Páginas 157-204 (Febrero 2021)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2359
Vol. 156. Núm. 4.
Páginas 157-204 (Febrero 2021)
Revisión

Tratamiento de la oftalmopatía de Graves

Treatment of Graves’ ophthalmopathy
Visitas
2359
Andrés González-Garcíaa,
Autor para correspondencia
andres.gonzalez@salud.madrid.org

Autor para correspondencia.
, Marco Sales-Sanzb
a Unidad de Enfermedades Sistémicas Autoinmunes y Minoritarias, Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, España
b CSUR de tumores orbitarios y cirugía de descompresión orbitaria en Oftalmopatía Tiroidea. Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, España
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Resumen

La oftalmopatía de Graves constituye una enfermedad inflamatoria con afectación fundamental de los músculos extraoculares y de la órbita, y representa la principal manifestación extratiroidea en los pacientes con enfermedad de Graves-Basedow. La etiopatogenia subyacente es inmunomediada mediante un mimetismo molecular con el receptor de la tirotropina en los fibroblastos oculares. El principal tratamiento en los casos moderados-graves se basa en la inmunosupresión sistémica, y son de elección los glucocorticoides a dosis altas. Sin embargo, algunos pacientes presentan intolerancia al tratamiento o mala respuesta a los glucocorticoides. En los últimos años se han descrito novedades terapéuticas en cuanto a la posología de los tratamientos inmunosupresores empleados, así como la irrupción de la terapia biológica en este campo. El objetivo de esta revisión es actualizar el tratamiento de la oftalmopatía inflamatoria, así como presentar opciones terapéuticas alternativas en aquellos casos corticorresistentes o con intolerancia a glucocorticoides.

Palabras clave:
Enfermedad de Graves-Basedow
Inflamación orbitaria
Orbitopatía
Glucocorticoides
Teprotumumab
Rituximab
Tocilizumab
Abstract

Graves’ ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and the orbit. It encompasses the most common extra-thyroid manifestation in patients with Graves-Basedow disease. The underlying cause is molecular mimicry with the TSH receptor in ocular fibroblasts, leading to an immuno-mediated pathogenesis. Glucocorticoids at high doses are the cornerstone in moderate-severe cases. However, some patients are corticorresistant or intolerant. In recent years, therapeutic novelties have been described in terms of the dosage of the immunosuppressive treatments used, as well as the emergence of biological therapy in this field. The objective of this review is to update the treatment of Graves’ ophthalmopathy, as well as to present alternative options in patients resistant or intolerant to glucocorticoids.

Keywords:
Graves-Basedow disease
Graves’ ophthalmopathy
Orbitopathy
Glucocorticoids
Teprotumumab
Rituximab
Tocilizumab

Artículo

Opciones para acceder a los textos completos de la publicación Medicina Clínica
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
R.S. Bahn.
Understanding the immunology of Graves’ ophthalmopathy. Is it an autoimmune disease?.
Endocrinol Metab Clin North Am, 29 (2000), pp. 287-296
[2]
W.M. Wiersinga.
Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy.
Lancet Diabetes Endocrinol, 5 (2017), pp. 134-142
[3]
R.S. Bahn.
Graves’ ophthalmopathy.
N Engl J Med, 362 (2010), pp. 726-738
[4]
D.H. Khoo, P.H. Eng, S.C. Ho, E.S. Tai, N.G. Morgenthaler, L.L. Seah, et al.
Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history, and thyrotropin receptor antibody levels.
Thyroid, 10 (2000), pp. 1093-1100
[5]
M. Frecker, V. Stenszky, C. Balazs, L. Kozma, E. Kraszits, N.R. Farid.
Genetic factors in Graves’ ophthalmopathy.
Clin Endocrinol (Oxf), 25 (1986), pp. 479-485
[6]
W.M. Wiersinga.
Quality of life in Graves’ ophthalmopathy.
Best Pract Res Clin Endocrinol Metab, 26 (2012), pp. 359-370
[7]
M.F. Prummel, W.M. Wiersinga, M.P. Mourits, L. Koornneef, A. Berghout, R. van der Gaag.
Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy.
Arch Intern Med, 150 (1990), pp. 1098-1101
[8]
G.B. Bartley.
The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.
Trans Am Ophthalmol Soc, 92 (1994), pp. 477-588
[9]
P. Vestergaard.
Smoking thyroid disorders--a meta-analysis.
Eur J Endocrinol, 146 (2002), pp. 153-161
[10]
P. De-Arriba-Palomero, M. Sales-Sanz, E. Fuentemilla, H.R. Won-Kim, F. De-Arriba-Palomero, F.J. Muñoz-Negrete.
Effectiveness of oral counselling for smoke cessation in Graves orbitopathy patients.
Arch Soc Esp Oftalmol, 94 (2019), pp. 323-330
[11]
M. Salvi, I. Campi.
Medical treatment of Graves’ orbitopathy.
Horm Metab Res, 47 (2015), pp. 779-788
[12]
C. Marcocci, G. Bruno-Bossio, L. Manetti, M.L. Tanda, P. Miccoli, P. Iacconi, et al.
The course of Graves’ ophthalmopathy is not influenced by near total thyroidectomy: A case-control study.
Clin Endocrinol (Oxf), 51 (1999), pp. 503-508
[13]
S.H. Acharya, A. Avenell, S. Philip, J. Burr, J.S. Bevan, P. Abraham.
Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: A systematic review.
Clin Endocrinol (Oxf), 69 (2008), pp. 943-950
[14]
L. Tallstedt, G. Lundell, O. Torring, G. Wallin, J.G. Ljunggren, H. Blomgren, The Thyroid Study Group, et al.
Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism.
N Engl J Med, 326 (1992), pp. 1733-1738
[15]
A. Lai, L. Sassi, E. Compri, F. Marino, P. Sivelli, E. Piantanida, et al.
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves’ orbitopathy: A retrospective cohort study.
J Clin Endocrinol Metab, 95 (2010), pp. 1333-1337
[16]
H.X. Li, N. Xiang, W.K. Hu, X.L. Jiao.
Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: A systematic review and meta-analysis.
J Endocrinol Invest, 39 (2016), pp. 1225-1233
[17]
G.J. Kahaly, S. Pitz, G. Hommel, M. Dittmar.
Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy.
J Clin Endocrinol Metab, 90 (2005), pp. 5234-5240
[18]
P.E. Macchia, M. Bagattini, G. Lupoli, M. Vitale, G. Vitale, G. Fenzi.
High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy.
J Endocrinol Invest, 24 (2001), pp. 152-158
[19]
H. Stiebel-Kalish, E. Robenshtok, M. Hasanreisoglu, D. Ezrachi, I. Shimon, L. Leibovici.
Treatment modalities for Graves’ ophthalmopathy: Systematic review and metaanalysis.
J Clin Endocrinol Metab, 94 (2009), pp. 2708-2716
[20]
L. Bartalena, G.E. Krassas, W. Wiersinga, C. Marcocci, M. Salvi, C. Daumerie, et al.
Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy.
J Clin Endocrinol Metab, 97 (2012), pp. 4454-4463
[21]
M. Moleti, G. Giuffrida, G. Sturniolo, G. Squadrito, A. Campennì, S. Morelli, et al.
Acute liver damage following intravenous glucocorticoid treatment for Graves’ ophthalmopathy.
Endocrine, 54 (2016), pp. 259-268
[22]
M. Marino, E. Morabito, M.R. Brunetto, L. Bartalena, A. Pinchera, C. Marocci.
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy.
Thyroid, 14 (2004), pp. 403-406
[23]
S.M. Young, A.Y.N. Lim, S.S. Lang, K.O. Lee, G. Sundar.
Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
[24]
L. Bartalena, L. Baldeschi, K. Boboridis, A. Eckstein, G.J. Kahaly, C. Marcocci, et al.
The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy.
Eur Thyroid J, 5 (2016), pp. 9-26
[25]
M. Bordaberry, D.L. Marques, J.C. Pereira-Lima, I.M. Marcon, H. Schmid.
Repeated peribulbar injections of triamcinolone acetonide: A successful and safe treatment for moderate to severe Graves’ ophthalmopathy.
Acta Ophthalmol, 87 (2009), pp. 58-64
[26]
R.A. Goldberg, Orbital steroid injections.
Br J Ophthalmol, 88 (2004), pp. 1359-1360
[27]
M.P. Mourits, M.L. van Kempen-Harteveld, M.B. Garcia, H.P. Koppeschaar, L. Tick, C.B. Terwee.
Radiotherapy for Graves’ orbitopathy: Randomised placebo-controlled study.
Lancet, 355 (2000), pp. 1505-1509
[28]
C.A. Gorman, J.A. Garrity, V. Fatourechi, R.S. Bahn, I.A. Petersen, S.L. Stafford, et al.
A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy.
Ophthalmology, 108 (2001), pp. 1523-1534
[29]
S.C. Wang, J. Wu, X.Q. Xie, X.L. Liu, Y. Luo, F. Wang, et al.
Comparison of IMRT and VMAT radiotherapy planning for Graves’ ophthalmopathy based on dosimetric parameters analysis.
Eur Rev Med Pharmacol Sci, 24 (2020), pp. 3898-3906
[30]
C. Marcocci, L. Bartalena, R. Rocchi, M. Marinò, F. Menconi, E. Morabito, et al.
Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy.
J Clin Endocrinol Metab, 88 (2003), pp. 3561-3566
[31]
J.C.A. Broen, J.M. van Laar.
Mycophenolate mofetil, azathioprine and tacrolimus: Mechanisms in rheumatology.
Nat Rev Rheumatol, 16 (2020), pp. 167-178
[32]
X. Ye, X. Bo, X. Hu, H. Cui, B. Lu, J. Shao, et al.
Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy.
Clin Endocrinol (Oxf), 86 (2017), pp. 247-255
[33]
G.J. Kahaly, M. Riedl, J. Konig, S. Pitz, K. Ponto, T. Diana, et al.
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): A randomised, observer-masked, multicentre trial.
Lancet Diabetes Endocrinol, 6 (2018), pp. 287-298
[34]
M. Riedl, A. Kuhn, I. Kramer, E. Kolbe, G.J. Kahaly.
Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy.
J Endocrinol Invest, 39 (2016), pp. 687-694
[35]
M. Salvi, D. Covelli.
B cells in Graves’ Orbitopathy: More than just a source of antibodies?.
Eye (Lond), 33 (2019), pp. 230-234
[36]
M.N. Stan, J.A. Garrity, B.G. Carranza Leon, T. Prabin, E.A. Bradley, R.S. Bahn.
Randomized controlled trial of rituximab in patients with Graves’ orbitopathy.
J Clin Endocrinol Metab, 100 (2015), pp. 432-441
[37]
M. Salvi, G. Vannucchi, N. Curro, I. Campi, D. Covelli, D. Dazzi, et al.
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study.
J Clin Endocrinol Metab, 100 (2015), pp. 422-431
[38]
M.N. Stan, M. Salvi.
Management of endocrine disease: Rituximab therapy for Graves’ orbitopathy - lessons from randomized control trials.
Eur J Endocrinol, 176 (2017), pp. R101-R109
[39]
A. Rubbert-Roth, D.E. Furst, J.M. Nebesky, A. Jin, E. Berber.
A review of recent advances using tocilizumab in the treatment of rheumatic diseases.
Rheumatol Ther, 5 (2018), pp. 21-42
[40]
S.C. Jyonouchi, R.W. Valyasevi, D.A. Harteneck, C.M. Dutton, R.S. Bahn.
Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves’ ophthalmopathy.
Thyroid, 11 (2001), pp. 929-934
[41]
J.V. Perez-Moreiras, J.J. Gomez-Reino, J.R. Maneiro, E. Perez-Pampin, A. Romo Lopez, F.M. Rodríguez Alvarez, et al.
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial.
Am J Ophthalmol, 195 (2018), pp. 181-190
[42]
T. Copperman, O.O. Idowu, R.C. Kersten, M.R. Vagefi.
Subcutaneous tocilizumab for thyroid eye disease: Simplified dosing and delivery.
Ophthalmic Plast Reconstr Surg, 35 (2019), pp. e64-e66
[43]
P.N. Taylor, L. Zhang, R.W.J. Lee, I. Muller, D.G. Ezra, C.M. Dayan, et al.
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
Nat Rev Endocrinol, 16 (2020), pp. 104-116
[44]
T.J. Smith, J. Janssen.
Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy.
Endocr Rev, 40 (2019), pp. 236-267
[45]
T.J. Smith, G.J. Kahaly, D.G. Ezra, J.C. Fleming, R.A. Dailey, R.A. Tang, et al.
Teprotumumab for thyroid-associated ophthalmopathy.
N Engl J Med, 376 (2017), pp. 1748-1761
[46]
R.S. Douglas, G.J. Kahaly, A. Patel, S. Sile, E.H.Z. Thompson, R. Perdok, et al.
Teprotumumab for the treatment of active thyroid eye disease.
N Engl J Med, 382 (2020), pp. 341-352
[47]
A. Markham.
Teprotumumab: First approval.
[48]
G. Kahaly, J. Schrezenmeir, U. Krause, B. Schweikert, S. Meuer, W. Muller, et al.
Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: A controlled, randomized and prospective study.
Eur J Clin Invest, 16 (1986), pp. 415-422
[49]
K.L. Yong, C.L. Chng, N. Ming Sie, S. Lang, M. Yang, A. Looi, et al.
Methotrexate as an adjuvant in severe thyroid eye disease: Does it really work as a steroid-sparing agent?.
Ophthalmic Plast Reconstr Surg, 35 (2019), pp. 369-373
[50]
N. Genere, M.N. Stan.
Current and emerging treatment strategies for Graves’ orbitopathy.
[51]
L. Iacobaeus, S. Sahlin.
Evaluation of quality of life in patients with Graves ophthalmopathy, before and after orbital decompression.
Orbit, 35 (2016), pp. 121-125
[52]
D.B. Rootman.
Orbital decompression for thyroid eye disease.
Surv Ophthalmol, 63 (2018), pp. 86-104
[53]
E.S. Al Qahtani, J. Rootman, J. Kersey, F. Godoy, C.J. Lyons.
Clinical pearls and management recommendations for strabismus due to thyroid orbitopathy.
Middle East Afr J Ophthalmol, 22 (2015), pp. 307-311
[54]
J.A. Evans, T.J.E. Clark, M.B. Zimmerman, R.C. Allen, J.A. Nerad, K.D. Carter, et al.
Rethinking our definition of postoperative success: A comparative analysis of three upper eyelid retraction repair techniques using novel metrics to capture functional and aesthetic outcomes.
Ophthalmic Plast Reconstr Surg, 34 (2018), pp. 55-63
asdasdasd
Opciones de artículo
Herramientas